Cargando…

Pharmacological Interventions for Primary Psychodermatologic Disorders: An Evidence Mapping and Appraisal of Randomized Controlled Trials

BACKGROUND: The lack of clinical guidelines for the treatment of primary psychodermatologic disorders (PPDs) hinders the delivery of optimal care to patients. The review aimed to identify, appraise, and summarize the currently available evidence about the safety and effectiveness of pharmacological...

Descripción completa

Detalles Bibliográficos
Autores principales: Turk, Tarek, Liu, Chaocheng, Fujiwara, Esther, Straube, Sebastian, Hagtvedt, Reidar, Dennett, Liz, Abba-Aji, Adam, Dytoc, Marlene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068402/
https://www.ncbi.nlm.nih.gov/pubmed/36802832
http://dx.doi.org/10.1177/12034754231155888
_version_ 1785018660458332160
author Turk, Tarek
Liu, Chaocheng
Fujiwara, Esther
Straube, Sebastian
Hagtvedt, Reidar
Dennett, Liz
Abba-Aji, Adam
Dytoc, Marlene
author_facet Turk, Tarek
Liu, Chaocheng
Fujiwara, Esther
Straube, Sebastian
Hagtvedt, Reidar
Dennett, Liz
Abba-Aji, Adam
Dytoc, Marlene
author_sort Turk, Tarek
collection PubMed
description BACKGROUND: The lack of clinical guidelines for the treatment of primary psychodermatologic disorders (PPDs) hinders the delivery of optimal care to patients. The review aimed to identify, appraise, and summarize the currently available evidence about the safety and effectiveness of pharmacological management of PPDs through randomized controlled trials (RCTs). METHODS: The Preferred Reporting Items for Systematic Review and Meta-Analyses (PRIMSA) statement and the Global Evidence Mapping Initiative guidance were followed. Medline, Embase, PsycInfo, Cochrane and Scopus were searched, and two reviewers independently completed article review, data extraction, and quality assessment. RESULTS: Among 2618 unique studies, full texts of 83 were reviewed and 21 RCTs were included. Five PDDs were identified: trichotillomania (n = 12), pathologic skin picking (n = 5), nail biting (n = 2), delusional parasitosis (n = 1), and dermatitis from compulsive hand washing (n = 1). Seven different classes of medications were investigated: SSRIs (i.e., fluoxetine, sertraline, and citalopram), tricyclic antidepressants (i.e., clomipramine and desipramine), antipsychotics (i.e., olanzapine and pimozide), anticonvulsant (i.e., lamotrigine), N-acetylcysteine, inositol, and milk thistle. RCT-derived evidence supports the use of antidepressants in trichotillomania (sertraline and clomipramine), pathologic skin picking (fluoxetine), pathologic nail biting and dermatitis from compulsive hand washing (clomipramine or desipramine); antipsychotics in trichotillomania (olanzapine) and delusional parasitosis (pimozide); N-acetyl cysteine in trichotillomania and skin picking. CONCLUSION: Few pharmacotherapies for primary psychodermatologic disorders are assessed through controlled trials in the literature. This review serves as a roadmap for researchers and clinicians to reach informed decisions with current evidence, and to build on it to establish guidelines in the future.
format Online
Article
Text
id pubmed-10068402
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-100684022023-04-04 Pharmacological Interventions for Primary Psychodermatologic Disorders: An Evidence Mapping and Appraisal of Randomized Controlled Trials Turk, Tarek Liu, Chaocheng Fujiwara, Esther Straube, Sebastian Hagtvedt, Reidar Dennett, Liz Abba-Aji, Adam Dytoc, Marlene J Cutan Med Surg Review Articles BACKGROUND: The lack of clinical guidelines for the treatment of primary psychodermatologic disorders (PPDs) hinders the delivery of optimal care to patients. The review aimed to identify, appraise, and summarize the currently available evidence about the safety and effectiveness of pharmacological management of PPDs through randomized controlled trials (RCTs). METHODS: The Preferred Reporting Items for Systematic Review and Meta-Analyses (PRIMSA) statement and the Global Evidence Mapping Initiative guidance were followed. Medline, Embase, PsycInfo, Cochrane and Scopus were searched, and two reviewers independently completed article review, data extraction, and quality assessment. RESULTS: Among 2618 unique studies, full texts of 83 were reviewed and 21 RCTs were included. Five PDDs were identified: trichotillomania (n = 12), pathologic skin picking (n = 5), nail biting (n = 2), delusional parasitosis (n = 1), and dermatitis from compulsive hand washing (n = 1). Seven different classes of medications were investigated: SSRIs (i.e., fluoxetine, sertraline, and citalopram), tricyclic antidepressants (i.e., clomipramine and desipramine), antipsychotics (i.e., olanzapine and pimozide), anticonvulsant (i.e., lamotrigine), N-acetylcysteine, inositol, and milk thistle. RCT-derived evidence supports the use of antidepressants in trichotillomania (sertraline and clomipramine), pathologic skin picking (fluoxetine), pathologic nail biting and dermatitis from compulsive hand washing (clomipramine or desipramine); antipsychotics in trichotillomania (olanzapine) and delusional parasitosis (pimozide); N-acetyl cysteine in trichotillomania and skin picking. CONCLUSION: Few pharmacotherapies for primary psychodermatologic disorders are assessed through controlled trials in the literature. This review serves as a roadmap for researchers and clinicians to reach informed decisions with current evidence, and to build on it to establish guidelines in the future. SAGE Publications 2023-02-20 /pmc/articles/PMC10068402/ /pubmed/36802832 http://dx.doi.org/10.1177/12034754231155888 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review Articles
Turk, Tarek
Liu, Chaocheng
Fujiwara, Esther
Straube, Sebastian
Hagtvedt, Reidar
Dennett, Liz
Abba-Aji, Adam
Dytoc, Marlene
Pharmacological Interventions for Primary Psychodermatologic Disorders: An Evidence Mapping and Appraisal of Randomized Controlled Trials
title Pharmacological Interventions for Primary Psychodermatologic Disorders: An Evidence Mapping and Appraisal of Randomized Controlled Trials
title_full Pharmacological Interventions for Primary Psychodermatologic Disorders: An Evidence Mapping and Appraisal of Randomized Controlled Trials
title_fullStr Pharmacological Interventions for Primary Psychodermatologic Disorders: An Evidence Mapping and Appraisal of Randomized Controlled Trials
title_full_unstemmed Pharmacological Interventions for Primary Psychodermatologic Disorders: An Evidence Mapping and Appraisal of Randomized Controlled Trials
title_short Pharmacological Interventions for Primary Psychodermatologic Disorders: An Evidence Mapping and Appraisal of Randomized Controlled Trials
title_sort pharmacological interventions for primary psychodermatologic disorders: an evidence mapping and appraisal of randomized controlled trials
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068402/
https://www.ncbi.nlm.nih.gov/pubmed/36802832
http://dx.doi.org/10.1177/12034754231155888
work_keys_str_mv AT turktarek pharmacologicalinterventionsforprimarypsychodermatologicdisordersanevidencemappingandappraisalofrandomizedcontrolledtrials
AT liuchaocheng pharmacologicalinterventionsforprimarypsychodermatologicdisordersanevidencemappingandappraisalofrandomizedcontrolledtrials
AT fujiwaraesther pharmacologicalinterventionsforprimarypsychodermatologicdisordersanevidencemappingandappraisalofrandomizedcontrolledtrials
AT straubesebastian pharmacologicalinterventionsforprimarypsychodermatologicdisordersanevidencemappingandappraisalofrandomizedcontrolledtrials
AT hagtvedtreidar pharmacologicalinterventionsforprimarypsychodermatologicdisordersanevidencemappingandappraisalofrandomizedcontrolledtrials
AT dennettliz pharmacologicalinterventionsforprimarypsychodermatologicdisordersanevidencemappingandappraisalofrandomizedcontrolledtrials
AT abbaajiadam pharmacologicalinterventionsforprimarypsychodermatologicdisordersanevidencemappingandappraisalofrandomizedcontrolledtrials
AT dytocmarlene pharmacologicalinterventionsforprimarypsychodermatologicdisordersanevidencemappingandappraisalofrandomizedcontrolledtrials